DataTrends Equity Research Group Releases Investor’s Corporate Profile® of Athersys, Inc.

Leesburg, VA, June 20, 2009 --(PR.com)-- The DataTrends Equity Research Group, a unit of DataTrends Publications, Inc., publisher of Stem Cell Business News and the Guide to Stem Cell Research Companies, today announced the release of its Investor’s Corporate Profile® of Athersys, Inc. (Nasdaq: ATHX) (“the Company”).

This timely, comprehensive report, published in PDF format, is available free of charge at http://www.stemcellresearchnews.com/DERG_Page.htm.

Athersys, Inc., has established an intriguing pipeline of developing therapeutic programs in multiple disease areas. The pipeline prominently features MultiStem®, a patented high-potential stem cell product being developed as a treatment for a broad array of disease indications. MultiStem® cells are manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources, and therefore avoid controversial ethical issues associated with embryonic stem cell technology. Athersys has conducted preclinical animal studies to evaluate the product’s safety and therapeutic benefit in various disease indications. Based on encouraging results of these and other studies, the Company in 2008 advanced two MultiStem® programs into clinical development, launching Phase I clinical trials in cardiovascular disease (treating patients that have suffered an acute myocardial infarction) and in oncology treatment support involving leukemia or lymphoma patients receiving bone marrow transplants to reduce the risk or severity of graft versus host disease.

Athersys believes that factors expressed by MultiStem® can reduce inflammation, protect damaged tissue, and form new blood vessels in regions of ischemic injury. If proven safe and effective in clinical trials, MultiStem® could prove to have significant commercial potential. MultiStem® cells may be expanded on a large scale for future clinical use and may be stored frozen until needed. Again, if proven safe and effective in human trials, MultiStem® has the potential to treat a range of disease indications, including ischemic injury and cardiovascular disease, certain neurological diseases, autoimmune disease, transplant support (including in oncology patients), and a range of orphan disease indications.

About DataTrends Publications, Inc., and DataTrends Equity Research Group

DataTrends Publications, Inc., founded in 1987, is the publisher of Stem Cell Research News (founded 1999), Stem Cell Business News (2002), and Stem Cell Lab World (2007), as well as semi-annual Guide to Stem Cell Research Companies. DataTrends Equity Research Group, a unit of DataTrends Publications, provides independent research to small, growth-oriented public companies. DERG’s Investor’s Corporate Profile® is a comprehensive, detailed summary of a company’s business and growth strategies, history, financial data, leadership, science & technology, commercial products and products in the pipeline, markets, competition, patent portfolio and other intellectual property, strategic alliances, and risk factors. The Profile does not forecast the market or provide target stock prices, and does not recommend buys, sells, or holds. DataTrends Publications, Inc., was not compensated by Athersys, Inc., in any way for the development of this Profile.

Forward-Looking Safe Harbor Statement

Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for Athersys, Inc., along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. These statements, and other forward-looking statements, are not guarantees of future performance. Investors should not place undue reliance on forward-looking statements contained in this press release. Neither DataTrends Publications, Inc., nor the subject of the Profile (“the Company”), undertake any obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

###